Evidence map›Paper›PMID 39529875›Full record

ArticleJournal of biomedical optics2024

Detection of breast cancer using machine learning on time-series diffuse optical transillumination data.

Nils Harnischmacher, Erik Rodner, Christoph H Schmitz

Abstract read
In one paragraph

Article in Journal of biomedical optics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nils HarnischmacherHTW - University of Applied Sciences Berlin, Faculty II, KI-Werkstatt, Berlin, Germany.ORCID 0009-0000-9702-4655
Erik RodnerHTW - University of Applied Sciences Berlin, Faculty II, KI-Werkstatt, Berlin, Germany.
Christoph H SchmitzHTW - University of Applied Sciences Berlin, Faculty I - Health Electronics, Biomedical Electronics and Applied Research (BEAR) Labs, Berlin, Germany.ORCID 0000-0001-8692-9248

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Significance: Optical mammography as a promising tool for cancer diagnosis has largely fallen behind expectations. Modern machine learning (ML) methods offer ways to improve cancer detection in diffuse optical transmission data. Aim: We aim to quantitatively evaluate the classification of cancer-positive versus cancer-negative patients using ML methods on raw transmission time series data from bilateral breast scans during subjects' rest. Approach: We use a support vector machine (SVM) with hyperparameter optimization and cross-validation to systematically explore a range of data preprocessing and feature-generation strategies. We also apply an automated ML (AutoML) framework to validate our findings. We use receiver operating characteristics and the corresponding area under the curve (AUC) to quantify classification performance. Results: For the sample group available ( Conclusions: ML offers a viable strategy for clinically relevant breast cancer diagnosis using diffuse-optical transmission measurements. The diagnostic performance of ML on raw data can outperform traditional statistical biomarkers derived from reconstructed image time series. To achieve clinically relevant performance, our ML approach requires simultaneous bilateral scanning of the breasts with spatially dense channel coverage.

Indexed as

Breast NeoplasmsMachine LearningSupport Vector MachineArea Under CurveBreastFemaleHumansImage Interpretation, Computer-AssistedImage Processing, Computer-AssistedOptical ImagingROC CurveTransilluminationbreast cancerdiffuse optical tomographymachine learningmammographyoptical mammography

Identifiers

PMID39529875
PMCPMC11552526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.